Structure via PubChem · Public domain (PubChem)
miglustat
Sign in to saveAlso known as N-butyl-1-deoxynojirimycin, NB-DNJ, Zavesca®, SC-48334, n-Butyl deoxynojirimycin, N-Butylmoranoline, N-(n-Butyl)deoxynojirimycin, Butyldeoxynojirimycin
Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease and Pompe disease.
Key facts
- Drug.ChEMBL
- 1029
- Drug.verifiedrevid
- 462252392
- Drug.image
- Miglustat.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.tradename
- Zavesca, Brazaves, Opfolda
- Drug.MedlinePlus
- a604015
- Drug.licence_EU
- yes
- Drug.DailyMedID
- Miglustat
- Drug.licence_US
- Miglustat
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- A16
- Drug.ATC_suffix
- AX06
- Drug.legal_AU
- S4
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C10H21NO4
- Molecular weight
- 219.28 g/mol
- IUPAC name
- (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol
- SMILES
- CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
- InChIKey
- UQRORFVVSGFNRO-UTINFBMNSA-N
- XLogP
- -0.6
- Polar surface area
- 84.2 Ų
- H-bond donors
- 4
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2002
- Admin. routes
- oral
- Indications
- HIV infection, Gaucher disease type 1, Glycogen storage disease due to acid maltase deficiency, disorder of glycogen metabolism
via ChEMBL · EBI
Research
619 papers- Miglustat.2012
- Miglustat.2006
- Miglustat.Drugs · 2003
- Miglustat (Zavesca®).1994
- Miglustat (Zavesca®).1994
via PubMed
Wikidata facts
- Mass
- 219.147
- Has use
- medication
Show 9 more facts
- chemical formula
- C₁₀H₂₁NO₄
- isomeric SMILES
- CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O
- subject has role
- enzyme inhibitor
- canonical SMILES
- CCCCN1CC(C(C(C1CO)O)O)O
- World Health Organisation international non-proprietary name
- miglustat
- defined daily dose
- 0.3
- medical condition treated
- Gaucher's disease
- stylized name
- migLUstat
- Commons category
- Miglustat
Sources (7)
via Wikidata · CC0
~5 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Mechanism of action
- Chemistry
- Society and culture
- Legal status
- Research
- References
Miglustat, sold under the brand name Zavesca among others, is a medication used to treat type I Gaucher disease and Pompe disease.
It was approved for medical use in the European Union in November 2002, and for medical use in the United States in July 2003.
Excerpted from Wikipedia’s “miglustat” article, available under the CC BY-SA 4.0 licence.